Application of protein and proteome in preparation of liver cirrhosis diagnostic reagent

Abstract

The invention relates to application of protein and proteome in preparation of a liver cirrhosis diagnostic reagent. The protein comprises Lumican, Tetranectin, Pro-platelet basic protein (PBP), Pigment epithelium-derived factor (PEDF), Insulin-like growth factor binding protein 3 (IGFbp-3), Sex hormone-binding globulin (SHBG), Thioredoxin and composition of parts in the liver cirrhosis diagnostic reagent. Multiple proteins related with health and disease states are identified and evaluated in large range by adopting a proteome technology, the screened biomarkers for identifying hepatitis and liver fibrosis are used for predicting the degree of hepatitis and liver fibrosis and can be used for preparing a kit for diagnosing liver cirrhosis and liver cirrhosis level, and the protein markers identify the sensitivity of liver cirrhosis and degree thereof; and by combining the optimal conditions of various protein markers, the sensitivity can reach 89 percent, the specificity reaches over 90 percent, and the sensitivity and the specificity are higher than those of any known detection method.

Description

technical field

[0001] This patent belongs to the field of detection reagents, especially the application of a protein and proteome in diagnostic reagents for liver cirrhosis. Background technique

[0002] Liver cirrhosis (Liver cirrhosis) is a common chronic liver disease, liver damage can be caused by one or more reasons, and the liver is progressive, diffuse, and fibrous. The specific manifestation is diffuse degeneration and necrosis of liver cells, followed by fibrous tissue hyperplasia and nodular regeneration of liver cells. These three changes are repeated and interlaced. As a result, the structure of liver lobules and blood circulation pathways are gradually remodeled, causing the liver to deform, harden and rot. lead to cirrhosis of the liver. The disease had no obvious symptoms in the early stage, but in the later stage, a series of portal hypertension and liver dysfunction occurred in different degrees, until the upper gastrointestinal bleeding, hepatic encephal...

Examples

Embodiment Construction

[0022] Below in conjunction with the examples, the present invention is further described, the following examples are illustrative, not limiting, and the protection scope of the present invention cannot be limited by the following examples.

[0023]Technical scheme of the present invention is as follows:

[0024] 1. Normal F0, hepatic fibrosis F1, F2, F3, F4, 6 cases in each group, were identified and graded by the Bartz and Ludwig method;

[0025] 2. Serum protein was removed by IgY12 Beckman system to remove 12 high-abundance proteins;

[0026] A) CyDye-marked protein----DIGE analysis---Decyder----statistical analysis---primary marker 1;

[0027] B) iTRAQ 8-labeled protein--iTRAQ analysis--statistical analysis--primary marker 2;

[0028] 3. Primary markers 1 and 2 are statistically analyzed---candidate markers;

[0029] 4. Establish ELISA for candidate markers and identify markers.

[0030] Specific steps are as follows:

[0031] Sample Analysis: Collection of samples (...

technical field

[0001] This patent belongs to the field of detection reagents, especially the application of a protein and proteome in diagnostic reagents for liver cirrhosis. Background technique

[0002] Liver cirrhosis (Liver cirrhosis) is a common chronic liver disease, liver damage can be caused by one or more reasons, and the liver is progressive, diffuse, and fibrous. The specific manifestation is diffuse degeneration and necrosis of liver cells, followed by fibrous tissue hyperplasia and nodular regeneration of liver cells. These three changes are repeated and interlaced. As a result, the structure of liver lobules and blood circulation pathways are gradually remodeled, causing the liver to deform, harden and rot. lead to cirrhosis of the liver. The disease had no obvious symptoms in the early stage, but in the later stage, a series of portal hypertension and liver dysfunction occurred in different degrees, until the upper gastrointestinal bleeding, hepatic encephal...

Examples

Embodiment Construction

[0022] Below in conjunction with the examples, the present invention is further described, the following examples are illustrative, not limiting, and the protection scope of the present invention cannot be limited by the following examples.

[0023]Technical scheme of the present invention is as follows:

[0024] 1. Normal F0, hepatic fibrosis F1, F2, F3, F4, 6 cases in each group, were identified and graded by the Bartz and Ludwig method;

[0025] 2. Serum protein was removed by IgY12 Beckman system to remove 12 high-abundance proteins;

[0026] A) CyDye-marked protein----DIGE analysis---Decyder----statistical analysis---primary marker 1;

[0027] B) iTRAQ 8-labeled protein--iTRAQ analysis--statistical analysis--primary marker 2;

[0028] 3. Primary markers 1 and 2 are statistically analyzed---candidate markers;

[0029] 4. Establish ELISA for candidate markers and identify markers.

[0030] Specific steps are as follows:

[0031] Sample Analysis: Collection of samples (...

Images